Jco Precision Oncology
Overview
Jco Precision Oncology is a scientific journal, published since 2017 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
JCO Precis Oncol
Start
2017
End
Continuing
e-ISSN
2473-4284
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 7562
48
SJR / Ranks: 976
2249
CiteScore / Ranks: 2159
8.20
JIF / Ranks: 1820
4.6
Recent Articles
1.
Wang J, Hou X, Peng L, Dang Y, Xu X, Wei C, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400605.
PMID: 40080756
Purpose: Combining radiotherapy with androgen deprivation therapy (ADT) is recommended for localized prostate cancer. However, the time required for significant therapeutic benefits is not well quantified. This study aims to...
2.
McCoy M, Yeang C, Bahnassy S, Tam S, Riggins R, Parashar D, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2300714.
PMID: 40080755
Purpose: Current precision medicine (CPM) matches patients to therapies using traditional biomarkers, but inevitably resistance develops. Dynamic precision medicine (DPM) is a new evolutionary guided precision medicine (EGPM) approach undergoing...
3.
Eriksen M, Hansen A, Nielsen A, Mundt F, Mann M, Lassen U, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400266.
PMID: 40080754
Purpose: It is a clinical challenge to select patients for BRAF-targeted therapy because of the lack of predictive biomarkers besides the BRAF V600E mutation. By analyzing the genome, transcriptome, and...
4.
Rajdev L, King G, Lieu C, Cohen S, Pant S, Uboha N, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400489.
PMID: 40048671
Purpose: Circulating tumor DNA (ctDNA) is an emerging tool in the evaluation of GI cancers. Challenges remain in defining its utility and role as a primary end point in therapeutic...
5.
Fan K, Chehade R, Fernandes I, Moravan V, Sahgal A, Warner E, et al.
JCO Precis Oncol
. 2025 Mar;
9:e2400641.
PMID: 40048670
Purpose: Human epidermal growth factor receptor 2 (HER2)-low is a newly defined subgroup of HER2-negative breast cancer. It is unknown whether HER2-low status is associated with brain metastases (BrM) development....
6.
Boer J, Koudijs M, Kester L, Sonneveld E, Hehir-Kwa J, Snijder S, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400788.
PMID: 40020210
Purpose: Treatment stratification in ALL includes diverse (cyto)genetic aberrations, requiring diverse tests to yield conclusive data. We optimized the diagnostic workflow to detect all relevant aberrations with a limited number...
7.
Staninova-Stojovska M, Matevska-Geshkovska N, Krstevska-Bozhinovikj E, Jovanovic R, Kubelka Sabit K, Angelovska B, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400901.
PMID: 40020209
No abstract available.
8.
9.
Trosman J, Weldon C, Kurian A, Mrig E, Phillips K
JCO Precis Oncol
. 2025 Feb;
9:e2400822.
PMID: 40020207
Purpose: Genomic testing is crucial in cancer risk identification, diagnosis, and treatment. However, health care implementation is challenging, even for tests covered by insurance. US payers are important health care...
10.
Biller L, Mittendorf K, Horiguchi M, Caruso A, Chittenden A, Ukaegbu C, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2500058.
PMID: 39991988
No abstract available.